Therapeutic Targeting Potential of Novel Silver Nanoparticles Coated with Anti-CD20 Antibody against Chronic Lymphocytic Leukemia

• Published in: Cancers 2023-07, Vol.15 (14), p.3618
• Main Authors: Adamo, Francesco Maria, Silva Barcelos, Estevao Carlos, De Falco, Filomena, Dorillo, Erica, Rompietti, Chiara, Sorcini, Daniele, Stella, Arianna, Del Papa, Beatrice, Baldoni, Stefano, Esposito, Angela, Geraci, Clelia, Arcaleni, Roberta, Pennetta, Chiara, Ragonese, Francesco, Moretti, Lorenzo, Mameli, Mariagrazia, Di Ianni, Mauro, Rosati, Emanuela, Fioretti, Bernard, Sportoletti, Paolo
• Format: Article
• Language: English
• Subjects: Antibodies; Apoptosis; Aqueous solutions; BAX protein; Bcl-2 protein; Bepridil; Bioavailability; Calcium influx; Cancer; Cancer therapies; Caspase; CD20 antigen; Chronic lymphocytic leukemia; Comparative analysis; Cytotoxicity; Drug development; Flow cytometry; Health aspects; Hematological diseases; Kinases; Leukemia; Lymphoma; Medical research; Nanoparticles; Oncology, Experimental; Patients; Rituximab; Silver; Software; Therapeutic targets; Xenografts
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15143618

Chronic lymphocytic leukemia (CLL) is an incurable disorder associated with alterations in several pathways essential for survival and proliferation. Despite the advances made in CLL therapy with the new target agents, in some cases, relapses and resistance could occur, making the discovery of new alternatives to manage CLL refractoriness necessary. To provide new therapeutic strategies for CLL, we investigated the anti-leukemic activity of silver nanoparticles (AgNPs), whose impact on CLL cells has been poorly explored. We studied the action mechanisms of AgNPs in vitro through flow cytometry and molecular analyses. To improve the bioavailability of AgNPs, we generated AgNPs coated with the anti-CD20 antibody Rituximab (AgNPs@Rituximab) and carried out imaging-based approaches and in vivo experiments to evaluate specificity, drug uptake, and efficacy. AgNPs reduced the viability of primary CLL cells and the HG-3 cell line by inducing an intrinsic apoptotic pathway characterized by Bax/Bcl-2 imbalance, caspase activation, and PARP degradation. Early apoptotic events triggered by AgNPs included enhanced Ca influx and ROS overproduction. AgNPs synergistically potentiated the cytotoxicity of Venetoclax, Ibrutinib, and Bepridil. In vitro, the AgNPs@Rituximab conjugates were rapidly internalized within CLL cells and strongly prolonged the survival of CLL xenograft models compared to each unconjugated single agent. AgNPs showed strong anti-leukemic activity in CLL, with the potential for clinical translation in combination with agents used in CLL. The increased specificity of AgNPs@Rituximab toward CLL cells could be relevant for overcoming in vivo AgNPs' non-specific distribution and increasing their efficacy.